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Pathogenesls of nephrolithiasis post-partial ileal bypass surgery: Case
control study. Between 1975 and 1983, 838 patients were randomized
into the Program on the Surgical Control of Hyperlipidemias (POSCH)
trial: 417 to standard medical care and 421 to partial ileal bypass (PIB)
surgery. During the course of the trial, an increased incidence of kidney
stone formation was found in the surgery group (4%/year) as compared
to the control group (0.4%/year). A matched triplet case-control study
was conducted to assess the possible causes for the increased incidence
of kidney stones, Three groups were studied: PIB stone-formers (S);
PIB non-stone formers (N); and non-PIB, non-stone formers in the
control group (C). Initially, 162 patients (54 triplets) were selected. Ten
percent of the patients declined to participate which resulted in a
sample size of 146 patients. The PIB patients had statistically significant
(P < 0.05) lower levels of serum vitamin D metabolites; lower urine
volume, pH, citrate, magnesium, carbon dioxide, and sulfate, and
higher urinary oxalate, ammonia and relative supersaturation for cal-
cium oxalate and uric acid than the control patients. Although S and N
had similar results, those S with no prior history of stones had a higher
calcium oxalate supersaturation than similar N with a negative prior
history of stones (P < 0.025). Based on these results, all PIB patients
appear to be at risk for kidney stone formation. The combination of
reduced urinary volume and calcium oxalate precipitation inhibitor
substance with increased calcium oxalate relative supersaturation pro-
duced an increase in nephrolithiasis risk in the PIB groups.
The incidence of kidney stones in hospitalized patients is
about 0.1% [1]. In a 25 year study, Johnson et al found an
annual age-adjusted incidence of kidney stones of 0.036% in
females and 0.123% in males [21. In patients with inflammatory
bowel disease with malabsorption, the incidence of kidney
stones may be as high as 7.2% [3] and, in patients who have had
jejuno-ileal bypass (JIB) for control of morbid obesity, the
incidence of kidney stones is as high as 10% [4—6]. The
incidence of kidney stones in partial ileal bypass (PIB) patients
has not been reported.
The Program on the Surgical Control of the Hyperlipidemias
(POSCH) is an ongoing, randomized, controlled trial in post-
myocardial infarction patients that is assessing the effect of
lowering blood cholesterol by PIB versus standard medical
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therapy on overall mortality [7, 8]. In the course of this study,
an increased incidence of urolithiasis (4% per year) was ob-
served in the PIB patients, as compared to the non-surgical
control group (0.4% per year). A multi-center study was de-
signed to evaluate the possible etiology for this increased
incidence of kidney stones.
Methods
Between 1975 and 1983, POSCH randomized 838 patients
(417 control and 421 surgery). Patients were randomly assigned
either to a control group which received standard medical
therapy or to a surgery group which received PIB surgery. The
PIB surgery involved bypassing one-third or 200 cm, whichever
was greater, of the distal small intestine. All patients, male or
female, were between 30 and 64 years of age, had survived one,
and only one, electrocardiogram and enzyme-documented myo-
cardial infarction, and had a total plasma cholesterol concen-
tration of at least 220 mg/dl or, if the total plasma cholesterol
was between 200 and 219 mg/dl, had a low density lipoprotein
cholesterol concentration of at least 140 mg/dl. A detailed
report of the POSCH patient selection criteria and design has
been published [9].
Three groups of patients within POSCH were studied. Group
I patients (S) were selected first and consisted of 54 surgery
group patients who had PIB and had formed at least one kidney
stone after randomization into POSCH. Group 11(N) consisted
of 54 PIB patients who had not formed stones since random-
ization into POSCH. Group III (C) consisted of control group
patients who had not had PIB and had not formed any stones
since the time of randomization into POSCH. Group II and
Group III patients were selected to match Group I patients with
respect to pre-randomization history of kidney stones (10 of 54
patients in each group), age, sex, time of randomization into
POSCR, and clinical center. After selection, 10% of the pa-
tients declined to participate, resulting in a sample size of 146
patients. Data on these patients, for the case-control study,
were collected between April 7, 1986, and April 28, 1987, during
a visit to a POSCH clinical center.
Two consecutive 24-hour urine collections were obtained.
These were analyzed for total volume, pH, ammonia, calcium,
carbon dioxide, citrate, creatinine, magnesium, oxalate, phos-
phorus, potassium, sodium, sulfate, and uric acid. Urine citrate
and urine oxalate analyses were performed at one of the
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Table 1. Kidney stone event rate
Follow-up
period
Control
—
Surgery
Person
years of
follow-up
Event'
rate
Person
years of
follow-up
Eventa
rate
0—1 Year
1—2 Years
2—3 Years
3—4 Years
4—5 Years
413
406
399
392
382
0.73
0.25
0.25
0.26
0.52
408
389
368
353
334
4.16
3.60
4.08
4.24
5.09
a Event rate is: (Number of Events/Patient years of follow-up) x 100
author's laboratories (K.H.). Urinary citrate levels were deter-
mined by spectrophotometry [101. Urinary oxalate values were
estimated by a quantitative enzymatic method using a standard
assay kit from Sigma Diagnostics (St. Louis, Missouri, USA).
The rest of the urine stone battery assay was performed by a
standard protocol at the Washington University Medical Cen-
ter, St. Louis, Missouri, Clinical Biochemistry Laboratory.
Relative supersaturations were determined for calcium oxalate,
uric acid, brushite and struvite utilizing the EQUIL-2 computer
program [11].
Fasting blood samples were obtained on these patients during
the two 24-hour urine collection periods. Sera were analyzed
for electrolytes, liver function tests, thyroxine, uric acid, and
complete blood count at the Smith Kline Bioscience laboratory
in Van Nuys, California, by standard automated analysis.
Serum parathyroid hormone (PTH) and 25 (OH) cholecalciferol
analyses were performed at one of the authors' laboratory
(K.H.). Carboxyl terminal PTH was assayed by a radioimmu-
noassay method previously described by Hruska et a! [121 and
25(OH) cholecalciferol in serum was measured by a competitive
protein binding radioassay [13]. In addition, I ,25(OH)2 chole-
calciferol levels were measured at the Smith Kline and French
Laboratory in St. Louis, Missouri, USA.
An extensive history, including dietary and beverage intake
and medication usage, was obtained. The number of bowel
movements was documented. A Kidney-Ureter-Bladder (KUB)
X-ray was performed on all patients (except pre-menopausal
females) during the clinic visits.
The urine data were examined in several ways: averaged,
separate days, and complete triplets. During the data collection
interval, there were seven (N) and three (C) patients who were
found to have stones post selection. In addition, after the data
collection interval, another seven (N) patients and one (C)
patient were found to have formed stones. Thus, the data were
also analyzed excluding subsequent stone-formers from the
non-stone-former groups and including subsequent PIB stone-
formers in the PIB stone-forming group. The results were
similar. The average of the two 24-hour urines with the patients
in their original groups was selected for use in this report. All
values reported here represent the mean of all the patients in
each group SEM where appropriate. Statistical analyses were
performed using an unpaired t-test. Separate analyses by male
and female was not performed. Multiple linear regression
analyses were also performed to ascertain whether a combina-
tion of variables could distinguish the N and S patients. Results
with a P value < 0.05 are considered statistically significant.
However, since no formal adjustment for multiple comparisons
Table 2. Stone formation among non-stone formers (N) and control
(C) patients according to prior history of kidney stones
Prior history of stones N C P
(+) Hx—Subsequent stone formation 4 2 NS
(+) Hx—No subsequent stone formation 6 7
(—) Hx—Subsequent stone formation 10 2 = 0.03
(—) Hx—No subsequent stone formation 32 35
Abbreviations are: (+) Hx, positive prior history of stones; (—) Hx,
negative prior history of stones.
has been used, P values between 0.05 and 0.01 should be
interpreted with caution.
Results
The patients in this study had been followed in POSCH
between 3.0 and 11.0 years at the time of the urine collection,
with an average follow-up of 6.5 years. The patients ranged in
age from 40 to 70 years with an average of 57.0 years. Only one
of the original triplets contained females, and ten of the triplets
contained patients who had a history of kidney stones prior to
randomization into POSCH. The median difference in ages
within triplets was 5.0 years and the median difference in time
since randomization into POSCH was 0.10 years.
The kidney stone event rate for each annual follow-up period
for five years is presented in Table 1. Within the surgery group,
the rate is relatively constant at approximately 4% per year.
The data on stone composition are very incomplete. However,
our best estimate is that approximately 70% of the stones are
calcium oxalate stones, since all S patients have had at least one
kidney stone episode after the PIB surgery. The N and C were
further analyzed according to their prior history of stone and
subsequent stone episode since surgery (Table 2). A prior
history of stone did not influence stone formation among the N
patients. Also N patients without a prior history of stones were
more likely to form new stones than the C patients (P = 0.03).
Table 3 presents a summary of the medical history and
physical examination results, including dietary and beverage
intake and frequency of bowel movements in the three patient
groups. The larger number of bowel movements per week in the
PIB patients was the only significant difference (24/week in the
surgical groups vs. 10/week in the control). There were no
differences in the total fluid intake and oxalate consumption
among the groups.
The blood and serum chemistry and hormonal profiles for the
three groups of patients were all within normal limits except for
the low levels of vitamin D metabolites [25(OH) vitamin D and
1,25(OH)2 vitamin D] in the PIB groups (Table 4).
Several significant differences were found in the analysis of
the 24-hour urine stone battery (Table 5). Both groups of PIB
patients produced less urine (S = 1344 mI/day, N = 1463
ml/day) than the non-PIB control patients (C = 1884 mI/day).
There was no difference, however, between the PIB stone-
formers and the PIB non-stone-formers.
PIB patients also had persistently lower urine pH. Both
fasting and post-prandial pH averages were <5.3 in the surgery
groups, as compared to >5.7 in the control group. In addition,
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Table 3. Summary of fluid and oxalate intake, bowel movement and some phys ical features
Differences among stone formers (S), non-stone formers (N),
and controls (C) P
S (49) N (51) C (46) S-C N-C S-N
Height cm 173.3 173.6 173.3
Weight kg 81.2 80.0 83.2
Quetelet gfcm2 2.7 2.7 2.8
BM's/week 23.7 1.7 23.6 1.4 10.3 0.6
a
a
a
b
a
a
a
b
a
a
a
a
Water oz/month 855.7 676.8 782.5
Juices oz/month 86.6 81.9 73.8
Milk oz/month 176.5 258.3 173.4
Soft drinks oz/month 193.1 162.7 222.0
a
a
a
a
a
a
a
a
a
a
a
Coffee oz/month 560.0 657.6 633.6
Tea oz/month 108.7 150.0 104.0
Beer ozjmonth 72.3 236.3 102.1
Wine oz/month 11.8 4.8 17.8
a
a
a
a
a
a
a
a
a
a
a
a
Liquor oz/month 1.6 4.3 5.2
Mixed drinks oz/month 73.0 33.1 79.1
Total fluids oz/month 2139.2 110.0 2265.7 131.9 2193.4 156.6
Oxalate mg/month 1061.5 116.4 1033.3 121.9 1049.0 159.5
a
a
a
a
a
a
a
a
a
a
a
a
a p> 0.05, difference within 1.0 SE
b P < 0.001, difference> 3.3 SE
Table 4. Summary of serum PTH and vitamin D metabolites
Differences among stone formers (5), non-stone
farmers (N), and controls (C) P
S-C N-C S-N5 (49) N (51) C (46)
Parathyroid hormone pJEq/ml 3.9 0.2 3.71 0.2 3.73 0.2
Vitamin D(25)hydroxy-D3 ng/mi 19.2 1.15 21.6 1.11 27.6 1.6
Vitamin D l,25(OH)2 D3 pg/mI 38.8 1.8 37.8 2.1 46.5
a
b
C
a
c
C
a
a
a
a p> 0.05, difference within 1.0 SEb P < 0.001, difference <3.3 SE
P < 0.05, difference <1.0 SE
the PIB groups were unable to generate an elevated urine pH
after a meal (Fig. 1).
The PIB groups had statistically significant lower levels of
urinary calcium, citrate, magnesium, carbon dioxide, sulfate,
uric acid, and potassium compared to the control group. Uri-
nary ammonia and oxalate levels were significantly higher in the
PIB groups than the control group.
The relative supersaturations (RS) for four urinary compo-
nents are shown in Figure 2. All patients had urine that was
supersaturated for calcium oxalate and uric acid. But the N and
S had higher RS and stone risk than C patients. However, when
data were broken down according to the presence or absence of
a prior history of kidney stones. Those S patients with no prior
history of stones, had a significantly higher RS for calcium
oxalate than their N counterpart (S = 6.09 0.7, N = 5.1 0.5;
P < 0.025). Both S and N had higher RS than C (C = 3.4 0.4;
S-C = P < 0.001; N-C P = <0.025). There were no significant
differences among all patients who have prior history of stones.
Although the PIB stone-formers had lower urine volume and
higher carbon dioxide, oxalate, magnesium and RS for calcium
oxalate and uric acid than the PIB non-stone-formers, these
differences were not statistically significant (Table 5, Fig. 2).
The 24-hour urine data, both 24-hour totals and concentrations
(data not shown), were employed in a multiple linear regression
analysis to see if some combination could predict stone-formers
in the PIB group. No meaningful statistically significant results
were found.
Medication intake by these patients was compiled over a
five-year follow-up duration. Over 200 different drugs were
recorded and they included steroid preparations, thiazide di-
uretics, non-steroidal anti-inflammatory drugs, vitamins A, D,
and C, antihypertensives, and calcium carbonate. All PIB
patients were prescribed calcium carbonate post-operatively.
More PIB stone-formers consistently ingested calcium carbon-
ate than the PIB non-formers, 80% versus 71%, at five-year
follow-up (data not shown).
Analysis of the number of calcium carbonate pills ingested
revealed that 53% of the stone-farmers versus 35% of the
non-farmers took 6 pills per day, a total of 3,600 mg of
elemental calcium per day.
Discussion
Acquired hyperoxaluria, with the associated increased inci-
dence of oxalate stones, has been well described in patients
with intestinal diseases and post-JIB [6, 14, 15]. Enhanced
intestinal oxalate absorption is the proposed mechanism [16].
Also, excess luminal bile salts and long-chain fatty acids have
been shown to increase the permeability of colonic epithelium
to oxalate [17]. The urinary oxalate was more elevated in the
PIB patients than in the non-surgical control patients, but this
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Table 5. Summary of urinary kidney stone battery profile
Differences among stone formers (S), non-stone formers (N),
24-hour urine totals
and controls (C) P
5 (49) N (51) C (46) S-C N-C S-N
Total volume ml 1343.9 74.6 1462.9 88.6 1884.2 96.3 e d c
pH 5.3 0.04 5.3 0.03 5.70 0,07 C C C
Ammonia mEq/24 hr 47.7 3.0 47.6 2.6 29.1 2.6 a a C
Calcium mg124 hr
Carbon dioxide mm Hg/24 hr
115.7 11.0 99.8 8.9 164.5 11.1
15.1 1.6 13.5 1.2 22.6 1.7
d
d
e C
c
Chloride mEq/24 hr 148.4 8.0 139.7 6.8 156.7 9.1 C C C
Citrate mg/24 hr 237.7 25.9 229.0 28.9 536.9 37.3 e C C
Creatinine mg/24 hr 1435.4 52.9 1419.7 46.7 1427.0 45.0 C C C
Magnesium mg/24 hr 45.6 3.1 38.1 2.8 99.1 6.8 e e C
Oxalate mg/24 hr 36.3 2.5 35.0 2.9 21.5 1.9 a a c
Phosphorus mg/24 hr 769.1 43.9 749.9 45.9 784.0 46.5 C C C
Potassium mEq/24 hr 47.3 3.0 46.0 2.1 64.0 3.3 C C C
Sodium mEqf24 hr 141.0 8.6 127.1 7.1 155.9 8.8 c d c
Sulfate mmol/24 hr 13.7 0.7 14.5 0.8 17.5 0.8 e d c
Uric acid mg/24 hr 521.6 32.1 502.5 32.6 638.9 36.4 I d c
The numbers in parenthesis indicate number of patients in each group.
a Difference >3.3 SE, P < 0.001b Difference >1.0 SE, P < 0.05
C Difference within SE, F> 0.05
d Difference <1.0 SE, P < 0.05
Difference <3.3 SE, P < 0.001
will result in increased reabsorption of unchelated citrate with
resultant hypocitraturia. Hypocitraturia can result from meta-
bolic acidosis [231, renal tubular acidosis (RTA) [24], incom-
plete distal RTA [251,potassium depletion [26, 27], starvation in
animal models [28], and acetazolamide intake [29]. In animal
models, vitamin D has been shown to increase urinary citrate
[30], but it is not clear if low vitamin D levels will lead to
•
hypocitraturia. The PIB patients had lower levels of 25(OH)
4 cholecalciferol and 1 ,25(OH)2 cholecalciferol.
Citrate is normally filtered and reabsorbed in the proximal
tubule by a sodium-citrate co-transporter. Metabolic acidosis
tends to increase citrate metabolism in the tubular cell mito-
chondria, therefore, resulting in low cellular concentration ofS
citrate and a net increase in reabsorption, that is, a low urinary
citrate concentration. Evans et al [27] and Clarke et a! [31]
showed in their studies that urine citrate may not be related to
urine pH, but to intracellular acid-base changes, as is the case
with acetazolamide which causes a high urine pH but low urine
citrate secondary to intracellular acidosis. No clinical acid-base
and electrolyte abnormalities were found in our PIB patients,
but the large number of bowel movements probably caused
significant gastrointestinal bicarbonate loss. This could explain
the altered post-prandia! alkaline tide.
Thiazide diuretics [321 and non-steroidal anti-inflammatory
drugs [33] have been shown to have hypocalciuric effects. No
correlation could be established between the urine calcium and
the use of these agents. Dietary sodium intake, on the other
hand, will influence urine calcium excretion. The urinary so-
dium was 10% higher among the stone-formers than the non-
formers. This would explain the slightly higher urinary calcium
excretion, but the consistently larger amount of calcium intake
by the stone-formers would certainly contribute to the hyper-
calciuria. Large quantities of calcium supplements often pre-
scribed to patients after ileal resection to protect against excess
6.000
5.500
5.000
+
+
I
a.
C
Post-prandial pH Morning pH
Fig. 1. Altered post-prandial alkaline tide among the PJB patients.
Both S and N were unable to elevate their urine pH after a meal. 5.3. vs.
5.7 in control (P < 0.001).
S N C
elevation was far less than that seen post-JIB when levels are
usually greater than 80 to 200 mg/dl [15, 161. This difference
may be related to the shorter length of bowel excluded in the
PIB procedure [7].
Some of the known inhibitors of urinary stone crystallization
and nucleation include pyrophosphates, magnesium, citrate [18,
19], and sulfate [20]. Among these, urine citrate is probably the
most potent inhibitor of stone crystallization, as it accounts for
about 50% of the urinary inhibitory activity [18] and it is a
potent inhibitor of crystal aggregation [21].
Gastrointestinal malabsorption from various causes will
cause hypocitraturia and hypomagnesuria [221. Magnesium
chelates with citrate in the urine, so that free citrate is unavail-
able for tubular reabsorption. Hence, low urinary magnesium
Fig. 2. Elevated relative supersaturation for calcium
oxalate and uric acid and increased stone risk among the
three groups of patients. Relatively low risk for brushite
and struvite stones. Symbols are: () stone-formers; (0)
non-stone-formers; () control.
oxalate absorption [34, 35], may actually predispose to stone
disease if hypercalciuria is induced. Despite the large calcium
intake among the stone-formers, their urine oxalate was still
slightly higher than those of the non-formers. The study design
did not allow for the assay of urinary nephrocalcin (a glycopro-
tein inhibitor of calcium oxalate crystal growth). It has been
reported that patients with calcium oxalate stones produce
nephrocalcin that differ from that produced by normal individ-
uals [36].
We conclude that lower urine volume, larger stool volumes,
hypocitraturia and high RS for calcium oxalate are probably the
most important factors leading to the 4% per year incidence of
kidney stones in PIB patients. Since urinary oxalate was
increased above the values seen in control patients, but not
above normal levels, we hypothesize that the increase in urine
oxalate is less important than the marked reduction in urine
citrate level. Seven of the patient selected originally as non-
stone-forming PIB patients were found to have stones during
the data collection period, and an additional seven patients in
this group have formed stones after the data collection period.
Taken together, the differences between the PIB patients (S and
N) and control patients could indicate an increased risk of
oxalate and uric acid stone disease in all patients who undergo
the PIB procedure. A prior history of kidney stones did not
appear to influence the risk.
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